NEW YORK, Oct. 30, 2012 \/PRNewswire\/ -- As many scientists and researchers are aware, biology entails an incredibly complex series of mechanisms and processes that still amaze intelligent minds today. While these biological systems have shaped the world, the application of modern biotechnology has only existed for approximately for three decades. According to a recent FundWeb article, this year marks the 30th anniversary of the \"first biotechnology drug approved for human medical use,\" known as Humulin, \"a genetically engineered version of natural human insulin for the treatment of diabetes.\" Since 1982, biotechnology has seeped its way into modern science and popular applications, which has led many to believe that biotechnology is the next \"technology super-cycle.\" David Lichtenstein, biotechnology supporter and BrainStorm Cell Therapeutics investor, agrees that the science certainly holds the potential to change culture and the way humans live and solve problems. <\/p>\n
David Lichtenstein states, \"It is amazing to look back at the last 30 years a small period in terms of scientific development and realize just how far biotechnology has come. I expect these applications to become more present in our society, improving every facet of daily life.\" According to the article, such varied use of biotechnology has been witnessed since the original introduction of Humulin. It states, \"Roughly two-thirds of all new drugs approved by the FDA have been discovered and\/or developed by a biotechnology company at some stage.\" In addition to medical use, biotechnology has encouraged significant changes in agriculture and industrial manufacturing.\" <\/p>\n
According to the article, financial analysts believe that biotechnology holds the potential for creating the next major socio-economic era in modern culture. It explains that such possibility for growth opens up a wide variety of investment opportunities in biotechnology. However, few have committed to investing in the science. Having already made significant investments in the field of biotechnology, David Lichtenstein knows that the industry holds promise. At BrainStorm Cell Therapeutics alone, there are projects that focus on repairing ALS, Multiple Sclerosis and Parkinson's disease through stem cell therapy. <\/p>\n
David Lichtenstein concludes, \"As far as investment strategies go, biotechnology is one field that is new, exciting and offers opportunity for long-term profit. After close examination, I believe wary investors may change their mind about investing in this incredible field of science.\" <\/p>\n
ABOUT: <\/p>\n
David Lichtenstein is a supporter of the growth of biotechnology and has become a major investor in the innovative science. He is currently an investor in BrainStorm Cell Therapeutics, a biotechnology company that develops adult stem cell therapies to resolve medical issues associated with severe neurodegenerative disorders including ALS, Multiple Sclerosis and Parkinson's disease. In addition, David Lichtenstein has proven his worth as an investment strategist, having steadily built the Lightstone Group since 1988. As chairman and CEO of the Lightstone Group, David Lichtenstein has carefully developed a diverse portfolio of properties allowing the company to become of the most widespread and successful privately held real estate companies in the United States of America. <\/p>\n<\/p>\n
Read more: NEW YORK, Oct. 30, 2012 \/PRNewswire\/ -- As many scientists and researchers are aware, biology entails an incredibly complex series of mechanisms and processes that still amaze intelligent minds today. Continue reading
\nDavid Lichtenstein: Biotechnology is Rich Area for Investment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"